ReviewCancers2024
Ocular Surface Side Effects of Novel Anticancer Drugs.
Review in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 24 citations in OpenAlex.
- Synthesis, anti-proliferative evaluation, DFT,RSC advances · 2026Article
- Ocular Toxicities of Anticancer Therapies in the Era of Precision Oncology: A Practical, Clinically Oriented Narrative Review.Biomedicines · 2026Review
- Molecular landscape connecting complications of dry eye disease: mechanisms, therapeutic targets, biomarkers, and future innovations.International ophthalmology · 2026Review
- Acral Lentiginous Melanoma With NRAS Mutation and Ocular Surface Toxicity Following Immunotherapy and Investigational KRASG12C Inhibitor: Case Report.Case reports in oncological medicine · 2026Article
- Synthesis and Evaluation of Carbon Black-Containing Hydrogels for the Adsorption of 5-Fluorouracil.Gels (Basel, Switzerland) · 2025Article
- Evaluation of the Ultrastructural Effects on Conjunctival Epithelial Cells of a New Multiple-Action Artificial Tear Containing Cross-Linked Hyaluronic Acid, Cationic Liposomes, and Trehalose with Transmission Electron Microscopy: A Pilot Study.Life (Basel, Switzerland) · 2025Article
- Recent advancements in polymer science for retinal diseases: New frontiers in drug delivery systems.APL bioengineering · 2025Article
- Bilateral optic neuropathy in Krukenberg tumor treated with FOLFOX plus nivolumab: a case report.BMC ophthalmology · 2025Article
- CDK4/6 inhibitor-associated vortex keratopathy: a case report.BMC ophthalmology · 2025Article
- Logic-gated approach for targeted delivery and site-selective activation of photothermal agents in precision cancer treatment.Chemical science · 2025Article
- Article
- Topical Chemotherapy for Ocular Surface Squamous Neoplasia: A Review of Adverse Effects and Their Clinical Management.Oncology research · 2025Review
- Possible viral agents to consider in the differential diagnosis of blepharoconjunctivitis.World journal of virology · 2024Article
- Side Effects of Novel Anticancer Drugs on the Posterior Segment of the Eye: A Review of the Literature.Journal of personalized medicine · 2024Review
- Trastuzumab-Induced Early Corneal Melt in HER2-Positive Breast Cancer: A Case Report and Review.The American journal of case reports · 2024Review
- Synthesis and biological research of new imidazolone-sulphonamide-pyrimidine hybrids as potential EGFR-TK inhibitors and apoptosis-inducing agents.RSC advances · 2024Article
- Safety Profile of the Trastuzumab-Based ADCs: Analysis of Real-World Data Registered in EudraVigilance.Biomedicines · 2024Article
- Bilateral neurotrophic keratitis associated with Gilteritinib therapy in a patient with acute myeloid leukemia: a case report.Romanian journal of ophthalmologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Surgery, anticancer drugs (chemotherapy, hormonal medicines, and targeted treatments), and/or radiation are common treatment strategies for neoplastic diseases. Anticancer drugs eliminate malignant cells through the inhibition of specific pathways that contribute to the formation and development of cancer. Given the ability of such pharmacological medications to combat cancerous cells, their role in the management of neoplastic diseases has become essential. However, these drugs may also lead to undesirable systemic and ocular adverse effects due to cyto/neuro-toxicity and inflammatory reactions. Ocular surface side effects are recognized to significantly impact patient's quality of life and quality of vision. Blepharoconjunctivitis is known to be a common side effect caused by oxaliplatin, cyclophosphamide, cytarabine, and docetaxel, while anastrozole, methotrexate, and 5-fluorouracil can all determine dry eye disease. However, the potential processes involved in the development of these alterations are yet not fully understood, especially for novel drugs currently available for cancer treatment. This review aims at analyzing the potential ocular surface and adnexal side effects of novel anticancer medications, trying to provide a better understanding of the underlying pharmacological processes and useful insights on the choice of proper management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.